Wednesday, June 29, 2016

BRIEF-Kiadis Pharma's ATIR101, has been granted an expansion to its existing orphan drug designation

* Kiadis Pharma's orphan drug designation for ATIR101 further expanded to include treatment

in a hematopoietic stem cell transplantation

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)